{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:00:10Z","timestamp":1773327610188,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate different starting doses of recombinant human follicle-stimulating hormone (rhFSH) on pregnancy outcomes for patients with normal ovarian reserve during gonadotropin- releasing hormone antagonist (GnRH-ant) protocol-controlled ovarian stimulation of <jats:italic>in vitro<\/jats:italic> fertilization (IVF) cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, a total of 1138 patients undergoing IVF cycles following the GnRH-ant protocol were enrolled. Patients were divided into two groups according to the starting dose of rhFSH. 617 patients received a starting dose of rhFSH of 150 IU, and 521 patients received a starting dose of rhFSH of 225 IU. We compared demographic characteristics, ovarian stimulation and embryological characteristics, and pregnancy and birth outcomes between the two groups. Multivariate logistic regression analysis was performed to examine the possible effects of the known potential confounding factors on pregnancy outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of oocytes retrieved in the 150 IU rhFSH group was significantly lower than those in the 225 IU rhFSH group. There was no significant difference between the two groups referring to embryological characteristics. The proportion of fresh embryo transfer in the 150 IU rhFSH group was significantly higher than that in the 225 IU rhFSH group (48.30% vs. 40.90%), and there was no difference in the risk of ovarian hyperstimulation syndrome and pregnancy outcomes between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In conclusion, the starting dose of rhFSH of 150 IU for ovarian stimulation has a similar pregnancy outcome as starting dose of rhFSH of 225 IU in GnRH-ant protocol for patients with normal ovarian reserve. Considering the potential cost-effectiveness and shorter time to live birth, the starting dose of rhFSH of 150 IU may be more suitable than 225 IU.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1068141","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:27:19Z","timestamp":1674192439000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of two different starting dose of rhFSH in GnRH antagonist protocol for patients with normal ovarian reserve"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhi-cheng","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-chang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-gao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12958-021-00814-0","article-title":"Cumulative live birth rates between gnrh-agonist long and gnrh-antagonist protocol in one art cycle when all embryos transferred: real-word data of 18,853 women from china","volume":"19","author":"Yang","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"Cd001750","DOI":"10.1002\/14651858.CD001750.pub4","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.875779","article-title":"Gnrh antagonist protocol versus gnrh agonist long protocol: a retrospective cohort study on clinical outcomes and maternal-neonatal safety","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.675670","article-title":"Optimising follicular development, pituitary suppression, triggering and luteal phase support during assisted reproductive technology: a delphi consensus","volume":"12","author":"Orvieto","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem285","article-title":"The ismaar proposal on terminology for ovarian stimulation for ivf","volume":"22","author":"Nargund","year":"2007","journal-title":"Hum Reprod"},{"key":"B6","doi-asserted-by":"publisher","first-page":"Cd012693","DOI":"10.1002\/14651858.CD012693.pub2","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (ivf\/icsi)","volume":"2","author":"Lensen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2013.07.008","article-title":"Anti-m\u00fcllerian hormone versus antral follicle count for defining the starting dose of fsh","volume":"27","author":"Lan","year":"2013","journal-title":"Reprod BioMed Online"},{"key":"B8","article-title":"Expert consensus on standardized application of gonadotropin-releasing hormone antagonist in assisted reproductive technology","volume":"42","year":"2022","journal-title":"Chin J Reprod Contraception"},{"key":"B9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/humupd\/dmq034","article-title":"Amh and afc as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis","volume":"17","author":"Broer","year":"2011","journal-title":"Hum Reprod Update"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in ivf using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e17329","DOI":"10.1097\/md.0000000000017329","article-title":"Frozen embryo transfer at the cleavage stage can be performed within the first menstrual cycle following the freeze-all strategy without adversely affecting the live birth rate: a strobe-compliant retrospective study","volume":"98","author":"Song","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der037","article-title":"The Istanbul consensus workshop on embryo assessment: Proceedings of an expert meeting","volume":"26","year":"2011","journal-title":"Hum Reprod"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.03.047","article-title":"Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine: an opinion paper","volume":"101","author":"Braakhekke","year":"2014","journal-title":"Fertil Steril"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.11.025","article-title":"Definitions of infertility and recurrent pregnancy loss: a committee opinion","volume":"113","year":"2020","journal-title":"Fertil Steril"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/humrep\/dew149","article-title":"Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials","volume":"31","author":"Humaidan","year":"2016","journal-title":"Hum Reprod"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh044","article-title":"A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 iu of recombinant fsh in women treated with the gnrh antagonist ganirelix for assisted reproduction","volume":"19","author":"Out","year":"2004","journal-title":"Hum Reprod"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.8.1676","article-title":"A prospective, randomized comparison of two starting doses of recombinant fsh in combination with cetrorelix in women undergoing ovarian stimulation for ivf\/icsi","volume":"16","author":"Wikland","year":"2001","journal-title":"Hum Reprod"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2010.02545.x","article-title":"A randomised controlled trial of 300 versus 225 iu recombinant fsh for ovarian stimulation in predicted normal responders by antral follicle count","volume":"117","author":"Jayaprakasan","year":"2010","journal-title":". Bjog"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2010.05.018","article-title":"The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles","volume":"21","author":"Fleming","year":"2010","journal-title":"Reprod BioMed Online"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Cd001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted conception","author":"Al-Inany","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a138602","article-title":"Endocrinology of the ovary","volume":"9","author":"Adashi","year":"1994","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.04.041","article-title":"Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers","volume":"98","author":"Ochsenk\u00fchn","year":"2012","journal-title":"Fertil Steril"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-016-0773-6","article-title":"What is the contribution of embryo-endometrial asynchrony to implantation failure","volume":"33","author":"Teh","year":"2016","journal-title":"J Assist Reprod Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.fertnstert.2016.04.024","article-title":"Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger","volume":"106","author":"Connell","year":"2016","journal-title":"Fertil Steril"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab160","article-title":"Is a freeze-all policy the optimal solution to circumvent the effect of late follicular elevated progesterone? a multicentric matched-control retrospective study analysing cumulative live birth rate in 942 non-elective freeze-all cycles","volume":"36","author":"Racca","year":"2021","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.fertnstert.2015.09.015","article-title":"Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles","volume":"105","author":"Healy","year":"2016","journal-title":"Fertil Steril"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deac103","article-title":"Con: freeze-all for all? one size does not fit all","volume":"37","author":"Vuong","year":"2022","journal-title":"Hum Reprod"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011184.pub3","article-title":"Fresh versus frozen embryo transfers in assisted reproduction","author":"Zaat","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa304","article-title":"High birth weight and large-for-gestational-age in singletons born after frozen compared to fresh embryo transfer, by gestational week: a nordic register study from the conartas group","volume":"36","author":"Terho","year":"2021","journal-title":"Hum Reprod"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011184.pub2","article-title":"Fresh versus frozen embryo transfers in assisted reproduction","author":"Wong","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab279","article-title":"Elective freezing of embryos versus fresh embryo transfer in ivf: a multicentre randomized controlled trial in the uk (e-freeze)","volume":"37","author":"Maheshwari","year":"2022","journal-title":"Hum Reprod"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-021-06306-1","article-title":"Does the freeze-all strategy improve the cumulative live birth rate and the time to become pregnant in ivf cycles","volume":"305","author":"Johnson","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/humrep\/dey388","article-title":"Higher probability of live-birth in high, but not normal, responders after first frozen-embryo transfer in a freeze-only cycle strategy compared to fresh-embryo transfer: a meta-analysis","volume":"34","author":"Bosdou","year":"2019","journal-title":"Hum Reprod"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.04.004","article-title":"Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes","volume":"114","author":"Schirmer","year":"2020","journal-title":"Fertil Steril"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil Steril"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex094","article-title":"High fsh dosing is associated with reduced live birth rate in fresh but not subsequent frozen embryo transfers","volume":"32","author":"Munch","year":"2017","journal-title":"Hum Reprod"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.742089","article-title":"Recombinant human follicle-stimulating hormone alfa dose adjustment in us clinical practice: an observational, retrospective analysis of a real-world electronic medical records database","volume":"12","author":"Mahony","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12958-021-00744-x","article-title":"Dose adjustment of follicle-stimulating hormone (fsh) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017)","volume":"19","author":"Fatemi","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00579","article-title":"Fsh requirements for follicle growth during controlled ovarian stimulation","volume":"10","author":"Abbara","year":"2019","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1068141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:27:22Z","timestamp":1674192442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1068141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":40,"alternative-id":["10.3389\/fendo.2023.1068141"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1068141","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"article-number":"1068141"}}